Veradermics’ stock grows on pivotal hair loss win
Veradermics’ share price has jumped more than 47% after its oral, extended-release version of minoxidil posted a win during a …
Post
-
-
Compass Therapeutics’s stock crashes after OS miss in BTC trial
Compass Therapeutics’ stock has dropped by more than 60% after a Phase II/III trial of its biliary tract cancer (BTC) …
-
Cellenkos receives FDA approval for CK0801 Phase II clinical trial
Cellenkos has received the US Food and Drug Administration (FDA) clearance to begin its Phase II clinical trial of CK0801 …
-
Study finds dose-response relationship between gestational age and autism risk
April is Autism Awareness Month, dedicated to increasing understanding, broadening opportunities, and creating change for people with autism spectrum disorder …
-
Oruka reports positive data from Phase IIa trial for plaque psoriasis
Oruka Therapeutics has reported positive interim data from the ongoing EVERLAST-A Phase IIa trial evaluating ORKA-001 in patients with moderate-to-severe …
-
HRS 2026: Medtronic, Boston Scientific and Abbott debut key PFA data
Boston Scientific, Abbott and Medtronic all presented successful readouts of their cardiac devices during the Heart Rhythm Society’s (HRS) 2026 …
-
Malaria vector Anopheles (Nyssorhynchus) darlingi evolving insecticide resistance
Malaria is a bloodborne parasitic disease wherein Plasmodium parasites are transmitted by mosquito vectors. Despite efforts to control mosquito populations, …
-
ESCMID Global 2026: Pritelivir excels in immunocompromised refractory HSV patients
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference, Phase III data for Aicuris’s pritelivir, …
-
Intellia’s in vivo gene therapy victorious in Phase III HAE trial
Intellia Therapeutics is set to seek US approval of its in vivo CRISPR gene therapy in hereditary angioedema (HAE) after …
-
Ascletis completes subject enrolment in Phase II ASC3 trial
Ascletis Pharma has completed subject enrolment in its 13-week US Phase II study of ASC30, an oral small molecule GLP-1 …
-
Kyowa Kirin and Kura initiate Phase II trial of ziftomenib for AML
Kyowa Kirin and Kura Oncology have started a Japanese Phase II registrational study of oral menin inhibitor ziftomenib in adult …
-
The slow march of clinical biomarkers to become surrogate endpoints
Clinicians have often pushed for certain biomarkers to move from serving a purely informative role in clinical trials to becoming …
-
AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, during a poster session, Axsome Therapeutics presented results …
-
Africa-Europe partnership delivers first clinical trial for malaria in early pregnancy
A partnership between Europe and Africa has seen the initiation of a clinical trial of an anti-malaria drug in early …
-
AAN 2026: Solengepras demonstrates emerging benefit in early Parkinson’s disease
At the American Academy of Neurology (AAN) 2026 annual conference, Cerevance reported findings from the Phase II ASCEND (NCT06006247) trial …